XPER compared with AMRX: revenue, margins and what each company keeps, and the suppliers and customers both name

XPERXperi Inc.

Mkt capRevenueRevenue

AMRXAmneal Pharmaceuticals, Inc.

Mkt capRevenueRevenue

Compare

XPERXperi Inc.

AMRXAmneal Pharmaceuticals, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

XPER

0 of 4at or beyond implied

Reportimpliedrealized× implied

Q2 FY26±13.3%▼−12.39%×0.93

May 7 '26±18.4%▲+11.88%×0.65

Q1 FY26±24.6%▲+3.96%×0.16

Q3 FY25±12.0%▲+1.93%×0.16

AMRX

0 of 4at or beyond implied

Reportimpliedrealized× implied

Q2 FY26±15.6%▼−3.14%×0.20

May 8 '26±10.1%▼−3.79%×0.38

= impliedXPER realized, solidAMRX realized, hatchedOne scale, both sides: full bar = 25%× = |realized| ÷ impliedspan: XPER 273d · AMRX 153dSource: market data

Q1 FY26

±21.3%

▼−1.54%

×0.07

Feb 27 '26±12.6%▼−4.69%×0.37

XPERXperi Inc.

5.31· pre 5.31· delayed

Mkt cap$258.1MRevenue$114MQ2 FY26Revenue$448MFY25

AMRXAmneal Pharmaceuticals, Inc.

21.50· pre 21.60

Pre-marketSep 2 '83

Mkt cap$6.9BRevenue$796MQ2 FY26Revenue$3.0BFY25

Compare

Pre-marketSep 2 '83

XPERXperi Inc.

AMRXAmneal Pharmaceuticals, Inc.

5.31pre 5.31delayed

Price

21.50pre 21.60

$258.1M

Mkt cap

$6.9B

Q2 FY26$114M

Revenue

$796MQ2 FY26

FY25$448M

Revenue

$3.0BFY25

XPER5.31vsAMRX21.50Pre-marketSep 2 '83